

Angiopoietin 1 and Vascular Endothelial Growth Factor Modulate Human Glomerular Endothelial Cell Barrier Properties

SIMON C. SATCHELL, KAREN L. ANDERSON, and PETER W. MATHIESON
Academic Renal Unit, University of Bristol, Southmead Hospital, Bristol, United Kingdom

Abstract. Normal glomerular filtration depends on the combined properties of the three layers of glomerular capillary wall: glomerular endothelial cells (GEnC), basement membrane, and podocytes. Podocytes produce endothelial factors, including angiopoietin 1 (ang1), and vascular endothelial growth factor (VEGF), whereas GEnC express their respective receptors Tie2 and VEGFR2 *in vivo*. As ang1 acts to maintain the endothelium in other vascular beds, regulating some actions of VEGF, these observations suggest a mechanism whereby podocytes may direct the unique properties of the glomerular endothelium. This interaction was investigated by studies on the barrier properties of human GEnC *in vitro*. GEnC were examined for expression of endothelium-specific markers by immunofluorescence and Western blotting and for typical responses to TNF- α by a cell-based immunoassay. Expression of angiopoietin and VEGF receptors was examined similarly. Barrier properties of GEnC monolayers cultured on

porous supports were investigated by measurement of transendothelial electrical resistance (TEER) and passage of labeled albumin. Responses to a cAMP analogue and thrombin were examined before those to ang1 and VEGF. Results confirmed the endothelial origin of GEnC and their expression of Tie2 and VEGFR2. GEnC formed monolayers with a mean TEER of 30 to 40 Ω/cm^2 . The cAMP analogue and thrombin increased and decreased TEER by 34.4 and 14.8 Ω/cm^2 , respectively, with corresponding effects on protein passage. Ang1 increased TEER by 11.4 Ω/cm^2 and reduced protein passage by 45.2%, whereas VEGF reduced TEER by 12.5 Ω/cm^2 but had no effect on protein passage. Both ang1 and VEGF modulate GEnC barrier properties, consistent with potential *in vivo* roles; ang1 stabilizing the endothelium and resisting angiogenesis while VEGF induces the high permeability to water, characteristic of the glomerular endothelium.

Angiopoietins (ang) and vascular endothelial growth factors (VEGF) form two groups of growth factors that are of particular importance in directing endothelial cell (EnC) behavior. These molecules are widely expressed and have essential and coordinated actions in physiologic regulation of vascular development, maturation, and permeability (1). They are also key players in pathologic angiogenesis and alterations in permeability (2) and as such have been implicated in major diseases, including cancer, diabetic retinopathy, and arteriosclerosis. Ang1 acts via the endothelial Tie2 receptor and in the adult continued expression of ang1 in periendothelial cells (3), and the phosphorylation of Tie2, even in quiescent vessels, suggests a role in vascular maintenance (4). Ang1 is unique in its ability to reduce EnC permeability (5) and seems to regulate some of the actions of VEGF, stabilizing the endothelium and resisting permeability increases, inflammation, and angiogenesis in the mature endothelium (5, 6). Ang2 is a competitive

antagonist of the actions of ang1 on the Tie2 receptor, and in the adult its expression is limited to tissues in which there is active remodeling (7). VEGF-A (often referred to simply as VEGF) is the most widely expressed member of the VEGF family and is present in a variety of biologically active isoforms arising by differential splicing, VEGF₁₆₅ being most abundant (8). Like ang1, VEGF is expressed by mural cells (including vascular smooth muscle cells [VSMC] and pericytes), which are well positioned to act as paracrine regulators of endothelial behavior. VEGF has powerful angiogenic and permeability-inducing effects acting through endothelial VEGF receptors (VEGFR1 to 3) (8).

We and others have shown that ang1 and VEGF are produced by podocytes in the adult renal glomerulus, whereas the adjacent glomerular EnC (GEnC) express the cognate receptors Tie2 and VEGFR1 and 2 (9–12). This suggests a relationship, analogous to that seen between mural cells and EnC in other vessels, whereby podocytes may influence endothelial phenotype and hence their contribution to the glomerular filtration barrier. Evidence in support of such an interaction is accumulating. Both experimental administration of neutralizing antibodies to VEGF and podocyte-specific reduction in VEGF production cause GEnC abnormalities, including swelling, vacuolation, and detachment along with proteinuria (13–15). The similar glomerular lesion of pre-eclampsia may be caused by reductions in circulating free VEGF (16), and use of a

Received September 18, 2003. Accepted November 29, 2003.
 Correspondence to Dr. Simon Satchell, Academic Renal Unit, University of Bristol, Southmead Hospital, Bristol, BS10 5NB, UK. Phone: +44-117-959-5437; Fax: +44-117-959-5438; E-mail s.c.satchell@bris.ac.uk

1046-6673/1503-0566

Journal of the American Society of Nephrology
 Copyright © 2004 by the American Society of Nephrology

DOI: 10.1097/01.ASN.0000115397.22519.03

VEGF-neutralizing antibody in clinical trials in treatment of metastatic carcinoma has been associated with proteinuria (17). We investigated the nature of this interaction further by examining effects of these mediators on barrier properties of human GEnC in culture.

Much debate has focused on which part of the glomerular filtration barrier is primarily responsible for restricting protein flux, but models indicate that the barrier functions as a whole, with each part making an essential contribution (18, 19). *In vivo*, GEnC form a continuous inner layer of the glomerular capillaries. Away from the nucleus, the cytoplasm is attenuated to 200 nm and is punctuated by numerous fenestrae: transcellular pores, 60 to 80 nm in diameter (20). Novel imaging techniques have demonstrated a GEnC glycocalyx of 200 to 400 nm in thickness, which covers both fenestrae and interfenestral domains (20). Whereas fenestrations are essential for the high hydraulic conductivity of the glomerular filtration barrier, the glycocalyx is likely to offer significant resistance to filtration of macromolecules (19, 21).

GEnC have been little studied in comparison with other glomerular cells and EnC from other origins. This is largely because GEnC have been difficult to culture, and few have published evidence of their successful isolation and propagation; fewer still have done so using human cells (22). However EnC from different organs, types of blood vessels, and species have different morphologies, behavior, and patterns of protein expression (23–25), indicating the importance of selecting the relevant EnC type for *in vitro* studies. GEnC have recently become available from a commercial source. We characterized these cells to confirm their endothelial origin and investigated their expression of Tie2 and VEGF receptors. We developed a system for studying the effects of ang1 and VEGF on GEnC permeability properties *in vitro* and hence to confirm the ability of these mediators to modulate GEnC characteristics that may be relevant to their barrier function *in vivo*. GEnC monolayers were grown on porous supports, and barrier formation was assessed by measurement of transendothelial electrical resistance (TEER) and passage of labeled albumin. Responses to mediators that are known to alter permeability of other EnC monolayers (a cAMP analogue and thrombin) (26, 27) were examined to validate the experimental system before the effects of ang1 and VEGF were studied.

Materials and Methods

Culture of GEnC

GEnC derived from decapsulated glomeruli isolated from normal human kidney (according to the supplier's data sheet) were obtained at passage 2 from the Applied Cell Biology Research Institute (Kirkland, WA). Cells were cultured in endothelial growth medium 2–microvascular (EGM2-MV; Cambrex, Wokingham, UK), made up from endothelial basal medium 2 (EBM2; Cambrex) and FCS (5%), antimicrobial agents, and growth factors as supplied. Cells that were being prepared for or being used in experiments were cultured in EGM2-MV without VEGF. Cells were used in experiments up to passage 8.

Immunofluorescence

Cells that were grown to confluence on collagen-coated (Autogen Bioclear, Calne, Wilts., UK) glass cover slips were fixed in 2% formaldehyde and permeabilized in 0.3% Triton X-100. Cells were incubated with blocking solution (5% FCS and 0.05% Tween 20 in PBS) and then with antibodies to platelet-endothelial cell adhesion molecule-1 (PECAM-1; R&D Systems, Minneapolis, MN), vascular endothelial (VE)-cadherin (Santa Cruz Biochemicals, Santa Cruz, CA), and von Willebrand factor (vWF; DakoCytomation, Ely, Cams, UK). Primary antibody binding was detected using FITC-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA). Control cells were incubated with secondary antibodies only. Coverslips were mounted in Vectashield aqueous mountant (Vector Laboratories, Peterborough, UK) and examined using a Leitz DMRB fluorescence microscope (Leica, Solms, Germany).

Subconfluent GEnC grown on coverslips were incubated with TNF- α (10 ng/ml; R&D Systems) in standard medium (EGM2-MV) or with control medium for 6 h. Cells were fixed, permeabilized, and labeled for e-selectin as above using a monoclonal antibody (R&D Systems). Control cells were labeled with an irrelevant primary antibody.

Cell-Based Fluorescence Immunoassay

A cell-based fluorescence immunoassay, essentially as described previously (22), was used to quantify changes in e-selectin expression in response to TNF- α . GEnC were seeded in 96-well plates at 10,000 cells/well. After 5 d, cells were treated with TNF- α (0 to 10 ng/ml; R&D Systems) in standard medium. After 6 h, the cells were fixed as above. Cells were incubated with an antibody to e-selectin that was detected with a FITC-labeled secondary antibody as above. Fluorescence emission at 520 nm after excitation at 490 nm was measured on a Packard Instruments FluoroCount fluorospectro-photometer (available through PerkinElmer Life Sciences, Boston, MA).

Western Blotting

Cultured GEnC were lysed in Laemmli sample buffer, and solubilized protein concentrations were determined (bicinchoninic acid assay; Pierce Chemical Co., Rockford, IL). Lysates of cultured human microvascular EnC (HMVEC; derived from adult lung tissue; Clonetics Corp., San Diego, CA), vascular smooth muscle cells (VSMC; gift from Dr. C. Shanahan, University of Cambridge, UK), and sieved glomeruli (as described previously (10)) were used as controls. Protein samples were separated by SDS-PAGE under reducing conditions and were blotted onto nitrocellulose membranes. The membranes were air-dried and blocked in 5% fat-free milk before incubation with antibodies to PECAM-1, VE-cadherin, vWF (as above), and actin (Sigma Chemical Co., St. Louis, MO) to confirm loading of comparable amounts of protein in each lane. After incubation with horseradish peroxidase-conjugated secondary antibodies, bands were detected by using the ECL chemiluminescence system (Amersham Biotech Ltd., Bucks, UK).

Expression of Tie2 and VEGF Receptors

Polyclonal antibodies were used to examine expression of Tie2 and VEGFR1 and 2 (all Santa Cruz) in cultured GEnC by immunofluorescence (IF) and Western blotting as above.

Culture of GEnC in Tissue-Culture Inserts

Polycarbonate supports (0.4- μ m pore size, 0.5-cm² surface area) in tissue-culture inserts (1-cm diameter; Nalge Nunc International,

Rochester, NY) were seeded with GEnC at passages 5 to 8 at 100,000 cells/cm². Inserts were placed in 24-well plates and were used for experiments between Days 5 and 12 after seeding.

Measurement of TEER

TEER was measured using an EVOMx voltohmmeter (World Precision Instruments, Sarasota, FL) connected to an Endohm 12 electrode chamber and cap (World Precision Instruments). The Endohm is designed for accurate quantitative measurements of lower resistance monolayers (e.g., endothelial rather than epithelial tissue cultures). The chamber and cap each contain a pair of concentric electrodes: a voltage-sensing silver/silver chloride pellet in the center and an annular stainless steel current electrode. The symmetrically apposing circular disc electrodes, situated above and beneath the membrane, allow uniform current density to flow across the membrane. The height of the upper Endohm 12 electrode was adjusted to 1 mm above the cell layer with an insert in place. The Endohm chamber was filled with 3 ml of medium, and the top electrode was replaced. Tissue-culture inserts were removed sequentially from culture plates and placed in the chamber, and the resistance was recorded after 10 s. The resistance of the endothelial monolayer was calculated as the total resistance measured minus the mean resistance of control inserts, with a correction for surface area. Formation of a satisfactory monolayer for use in experiments was taken to be indicated by a TEER $\geq 20 \Omega/\text{cm}^2$.

Measurement of Transendothelial Protein Passage

Transendothelial permeability to macromolecules was assessed by measuring passage of FITC-labeled BSA (Sigma) across the monolayer. The method was based on a published protocol (28). Medium in both well and insert containing GEnC monolayers was replaced with serum-free medium (SFM; EBM2). After 1 h, the medium in the insert was replaced with 500 μl of SFM containing 0.5 mg/ml FITC-labeled BSA; that in the well was replaced with 500 μl of SFM containing 0.5 mg/ml unlabeled BSA (Sigma). At 1, 2, and 3 h, 100- μl aliquots were removed and replaced with 100 μl of SFM containing unlabeled BSA (0.5 mg/ml). The fluorescence of the aliquots was measured as above, and the concentration of FITC-BSA was calculated by reference to a set of standard dilutions.

Effect of cAMP and Thrombin on GEnC Monolayer Barrier Properties

The effect of a cAMP analogue was examined as a control for the system as increasing intracellular cAMP decreases permeability in other EnC (26). Cell membranes are impermeable to cAMP, so a cell membrane-permeable cAMP analogue, 8-(4-chlorophenylthio) (pCPT)-cAMP (Sigma), was used in combination with a cAMP-specific phosphodiesterase inhibitor, RO-20-1724 (CN Biosciences, Nottingham, UK) to elicit a maximal response. Conversely, thrombin increases permeability in other EnC monolayers (27). Culture medium in both wells and inserts was replaced with SFM. Baseline TEER was measured after 1 h, and the culture medium was again replaced, this time with SFM containing 20 μM RO-20-1724 and 300 μM pCPT-cAMP ("cAMP medium"), 1 U/ml thrombin (Sigma), or control medium. TEER was measured at 1 h. The effects of cAMP and thrombin on FITC-BSA passage were measured as above, adding the agonists in the above concentrations with the BSA in SFM solutions.

Effect of Ang1 and VEGF on Monolayer Barrier Properties

Effects of recombinant ang1 (100 ng/ml; R&D Systems) and recombinant VEGF₁₆₅ (50 ng/ml; R&D Systems) on TEER of GEnC

monolayers were measured as for cAMP and thrombin above. TEER was measured at various time points. In some experiments, a soluble Tie2/Fc receptor chimera (1 $\mu\text{g}/\text{ml}$; R&D Systems) was added to the ang1 solution 30 min before application to monolayers to bind ang1 and block its interaction with cell-surface Tie2 receptors. In other experiments, ang1 and VEGF were added sequentially. Experiments to examine the effect of ang1 and VEGF were repeated using serum-containing medium (EGM2-MV). The effects of ang1 and VEGF on FITC-BSA passage were measured as above, adding the agonists in the above concentrations with the BSA in SFM solutions.

Statistical Analyses

Microsoft Excel software (Microsoft Corporation, Redmond, WA) was used for simple statistics, including means and *t* tests. SPSS 11.0 (SPSS, Chicago, IL) was used for other tests, including SEM and ANOVA. *P* < 0.05 was taken to indicate statistical significance.

Results

GEnC Culture and Characterization

Commercially available GEnC had typical endothelial appearances on light microscopy, having bright perinuclear halos and growing to form confluent monolayers of polygonal cells at passage 8 or less. At later passages, cultures began to show signs of senescence. IF confirmed expression of endothelial-specific proteins in the expected distribution (Figure 1). vWF staining was cytoplasmic, whereas the adhesion molecules PECAM-1 and VE-cadherin were expressed at cell junctions. Western blotting for the same proteins confirmed their expression in GEnC (Figure 2). vWF and VE-cadherin were expressed equally in GEnC and HMVEC, but PECAM-1 expression was lower in GEnC.

Treatment of GEnC with TNF- α increased expression of e-selectin by IF (Figure 3) but had no effect on binding of an irrelevant primary antibody (not shown). This typical EnC




Figure 1. Immunofluorescence staining showing expression of endothelial cell (EnC)-specific markers by human glomerular EnC (GEnC) cultured on coverslips. Magnification, $\times 200$.




Figure 2. Western blotting analyses of protein extracted from GEnC, human microvascular endothelial cells (HMVEC), vascular smooth muscle cells (VSMC), and glomeruli sieved from normal renal cortex (Gloms) demonstrating the expression of EnC-specific markers (von Willebrand factor, vascular endothelial cadherin, and platelet-endothelial cell adhesion molecule-1) in GEnC. Images were derived from identical gels with each lane loaded with the same amount (20 μg) of the same protein samples. Actin bands confirm the loading of comparable amounts of protein. Numbers indicate expected molecular weight of bands and correspond with molecular weights of marker proteins (not shown).




Figure 3. Immunofluorescence showing the effect of TNF-α on e-selectin expression by GEnC. GEnC grown on glass coverslips were incubated with 10 ng/ml TNF-α or control medium for 6 h before fixing and labeling for e-selectin. Magnification, ×400.

response was shown to be dose dependent by cell-based fluorescence immunoassay (Figure 4). 10 ng/ml TNF-α caused a 3.8-fold increase in e-selectin expression over 6 h.

Expression of Tie2 and VEGF Receptors by Cultured GEnC

GEnC were shown to express VEGFR2 and Tie2 by IF (not shown) and Western blotting (Figure 5). Although VEGFR1 seemed to be expressed on IF, this was not confirmed by Western blotting, whereas there was a strong band for VEGFR2. Tie2 consistently appeared in Western blotting as a triplet in cultured cell lysates and a single band in tissue lysates, suggesting differences in posttranslational processing.

Culture of GEnC in Tissue-Culture Inserts

GEnC monolayers reached a mean TEER of 30 to 35 Ω/cm² within 7 d with an additional, more gradual increase to 35 to 40




Figure 4. Chart showing the effect of TNF-α on e-selectin expression by GEnC in a cell-based fluorescence immunoassay. GEnC were incubated with TNF-α at various concentrations or control medium for 6 h before fixing and labeling for e-selectin. E-selectin expression is proportional to fluorescence emission. Bars show mean ± SEM; n = 12; P < 0.001 by ANOVA.




Figure 5. Western blotting analyses of protein extracts as in Figure 2 demonstrating the expression of the receptors VEGFR2 and Tie2 in cultured GEnC. Images were derived from identical gels with each lane loaded with the same amount (20 μg) of the same protein samples. Numbers indicate expected molecular weight of bands and correspond with molecular weights of marker proteins (not shown).

Ω/cm² at 14 d (data not shown). FITC-BSA passage across monolayers decreased correspondingly.

Effects of cAMP and Thrombin on Monolayer Barrier Properties

Increasing the effective intracellular concentration of cAMP by use of the cAMP medium increased the mean TEER of GEnC monolayers relative to controls by 34.4 Ω/cm² over 1 h, whereas thrombin decreased TEER by 14.8 Ω/cm² (Figure 6). Treatment with cAMP medium caused a corresponding decrease in passage of FITC-BSA (by 51% over 3 h), whereas thrombin produced the opposite effect (increasing FITC-BSA passage over 3 h by 301%; Figure 7).

Effect of Ang1 and VEGF on Monolayer Barrier Properties

Ang1 increased TEER of GEnC monolayers by a maximum of 11.4 Ω/cm², whereas VEGF had the opposite effect, decreasing TEER by 12.5 Ω/cm² (Figure 8). Addition of the Tie2/Fc chimera reduced the effect of ang1 on TEER by 64.3%




Figure 6. Chart showing the results of separate experiments examining the effect of cAMP medium (containing 2 μ M RO-20-1724 and 30 μ M pCPT-cAMP) or thrombin (1 U/ml) on transendothelial electrical resistance (TEER) of GEnC monolayers after 1 h. Bars show mean \pm SEM; $n = 5$, $P = 0.006$ for effect of cAMP; $n = 8$, $P < 0.0005$ for effect of thrombin, P values by t test. cAMP medium increased TEER by 34.4 Ω/cm^2 compared with control, whereas thrombin decreased TEER by 14.8 Ω/cm^2 .

at 1 h ($P < 0.005$ by repeated measures ANOVA, not shown), confirming that the effect of ang1 on TEER was predominantly due to Tie2 binding. When the experiment was repeated using serum-containing medium, similar, although less pronounced, effects were observed (Figure 9). When ang1 and VEGF were added sequentially, both agonists exerted effects comparable in magnitude and direction with those observed in previous experiments (Figure 10).

Ang1 decreased FITC-BSA passage across GEnC monolayers over 3 h by 45.2% (Figure 11), consistent with the observed increase in TEER. VEGF did not increase the passage of FITC-BSA despite its effects on TEER, which were of similar magnitude to those of both thrombin and ang1 (in the same and opposite directions, respectively). However, concurrent addition of VEGF partially abrogated the effect of ang1 in decreasing protein passage.

Discussion

Commercially available human GEnC were derived from sieved glomeruli, and contamination with nonglomerular en-

dothelium therefore is negligible. Our results show that these cells maintain endothelial phenotype and function *in vitro*. The expression of Tie2 and VEGFR2 by cultured GEnC is consistent with observations of their expression *in vivo*. In the mature animal, the majority of VEGF actions on EnC, including survival, proliferation, chemotaxis (all important in angiogenesis), and induction of permeability, are mediated through VEGFR2 (8).

GEnC formed monolayers in culture with mean TEER of 30 to 40 Ω/cm^2 , comparable both with other microvascular EnC studied in our laboratory (HMVEC as above; data not shown) and with published data using other EnC types. TEER are generally reported in the range of 6.1 to 69 Ω/cm^2 (29). Endothelia that form a highly restrictive blood-organ barrier *in vivo* such as brain and retinal microvascular endothelia show the highest TEER in culture with values of 186.6 Ω/cm^2 recorded in bovine retinal EnC (29, 30). Because a variety of different tracers and methods have been used for measuring macromolecular permeability, it is difficult to compare directly results of protein passage measurements. TEER is a measure of ion flux and is often used as an indicator of the pathways across a cell layer open to water and small molecules. These pathways include those that are accessible to macromolecules, known to be mainly interendothelial gaps in other cultured EnC monolayers (29). Variations in fractional area of these gaps between different monolayers are likely to explain differences in TEER and protein passage between individual monolayers. GEnC have a unique phenotype *in vivo*, yet no previously published studies have described their *in vitro* permeability characteristics.

The cAMP medium and thrombin provided good controls, demonstrating the ability of this system to detect changes in ion flux and macromolecular passage across GEnC monolayers. GEnC behavior in response to these mediators was similar to that reported for other EnC (26, 27). Both cAMP and thrombin effect monolayer integrity through modulation of the size of intercellular gaps, determined by the balance between cytoskeletal tension, which tends to pull cell junctions apart, and




Figure 7. Graphs showing the effect of “cAMP medium” (containing 2 μ M RO-20-1724 and 300 μ M pCPT-cAMP; A) or thrombin (1 U/ml; B) on passage of FITC-BSA through GEnC monolayers over time. Points show mean \pm SEM, $n = 10$, $P = 0.003$ for effect of cAMP; $n = 10$, $P < 0.0005$ for effect of thrombin by repeated measures [rm] ANOVA.




Figure 8. Chart showing the results of separate experiments examining the effect of angiotensin 1 (ang1; 100 ng/ml) and vascular endothelial growth factor (VEGF; 50 ng/ml) on TEER of GEnC monolayers over time using serum-free medium. Bars show mean ± SEM relative to control values; $n = 16$, $P = 0.0008$ for effect of ang1; $n = 8$, $P < 0.0005$ for effect of VEGF by rmANOVA. Ang1 increased TEER maximally by $11.4 \Omega/\text{cm}^2$ at 1 h, whereas VEGF decreased TEER by $12.5 \Omega/\text{cm}^2$ at 1 h.




Figure 9. Chart showing the results of separate experiments examining the effect of ang1 (100 ng/ml) and VEGF (50 ng/ml) on TEER of GEnC monolayers over time using serum-containing medium. Bars show mean ± SEM relative to control values; $n = 8$ in each case, $P < 0.0005$ and 0.002 , respectively, by rmANOVA. Ang1 increased TEER maximally by $6.75 \Omega/\text{cm}^2$ at 30 min, whereas VEGF decreased TEER by $7.5 \Omega/\text{cm}^2$ at 30 min.

the actions of junctional adhesion molecules, including VE-cadherin (31). Cytoskeletal tension is dependent on the activity of nonmuscle myosin light chain (MLC) kinase, an enzyme required to initiate actin-myosin interaction by phosphorylating MLC. Increased cAMP is accompanied by a reduction in MLC phosphorylation and therefore also in contractility (32). Thrombin induces calmodulin-dependent phosphorylation of MLC and inhibition of MLC phosphatase (27).

Ang1 caused an increase in TEER of GEnC monolayers and a corresponding decrease in protein passage, indicating an increase in the integrity of the monolayer. The effect on TEER was of a similar magnitude to that of VEGF, although in the opposite direction. These are the first data confirming that ang1 has effects on permeability measures in cultured microvascular EnC and on TEER of any cells. The one previous investigation of ang1 effects on barrier function *in vitro* used macrovascular cells and studied protein passage only, showing a similar effect




Figure 10. Graph showing effect on TEER of GEnC monolayers over time when ang1 (100 ng/ml) and VEGF (50 ng/ml) were added sequentially. Arrows indicate timing of replacement of media with media-containing agonists or control media as indicated in key. Mean ± SEM relative to group of inserts treated with control media throughout; $n = 8$ in each group, $P = 0.022$ for effect of ang1 and $P = 0.011$ for effect of VEGF by rmANOVA.




Figure 11. Graph showing the effect of ang1 (50 ng/ml) and VEGF (100 ng/ml), alone or in combination, on passage of FITC-BSA through GEnC monolayers over time. Mean ± SEM, $n = 10$, $P < 0.0005$ by rmANOVA. *Post hoc* comparisons (Bonferroni) ang1 versus control and versus VEGF both $P < 0.0005$, ang1 versus ang1+VEGF $P = 0.089$, others nonsignificant.

(33). The current study adds the additional information that ang1 does not prevent VEGF from having an effect, as suggested in Gamble's paper (33); rather the barrier function of monolayers treated with both agonists was the result of their combined actions. It is intriguing that despite decreasing TEER, VEGF had no effect on FITC-BSA passage in these experiments, suggesting that in GEnC it has a greater effect on small-diameter pathways across the monolayer than on those open to macromolecules. This is consistent with an *in vitro* role for VEGF in the induction of the high hydraulic conductivity of GEnC. Taken together, these observations confirm the potential of ang1 and VEGF to have effects on GEnC phenotype and maintenance of barrier properties as a result of their combined actions *in vivo*.

The reduction in magnitude of the effects of ang1 and VEGF when examined in serum-containing medium may be due to blockade by serum proteins or specific inhibitors (*e.g.*, soluble VEGFR1 and Tie2 (16, 34)). Such inhibitors may moderate systemic effects of these mediators while allowing paracrine

actions. Both ang1 and VEGF have matrix-binding properties and so may become incorporated in the glomerular basement membrane, whereas EnC have the ability to utilize these matrix-bound mediators (35, 36).

It is likely from this and previous studies that the observed effect of ang1 was mediated through effects on junctional proteins, strengthening cell–cell adhesion (33). This effect is consistent with a stabilizing action on GEnC *in vivo*. Similarly, the decrease in TEER caused by VEGF suggests a parallel effect *in vivo*. In other studies, VEGF has been shown to have various potentially relevant effects, including phosphorylation of VE-cadherin (weakening cell–cell adhesion) and induction of transcellular holes, vesiculovacuolar organelles, and fenestrations (37). Any of these may have contributed to the effects observed here, although, as above, the results suggest a greater effect on small-diameter pathways. Furthermore, that thrombin, acting on cell junctions, both decreased TEER and increased protein passage suggests an alternative mode of action for VEGF in these experiments. The action of ang1 on intercellular junctions while VEGF acts primarily via effects on another transmonolayer pathway suggests a way in which the seemingly opposing actions of these mediators may be complementary *in vivo*. Future ultrastructural studies will examine in detail the mechanisms of the observed effects. This model will be useful for further studies of GEnC barrier properties and their contribution to glomerular permselectivity.

That GEnC are responsive to these important mediators *in vitro* suggests that some of their actions (on EnC survival, proliferation, and barrier properties) may have therapeutic applications in glomerular disease. Endothelial damage is a central component of glomerular diseases, including hemolytic-uremic syndrome (22) and pre-eclampsia (16), and may also play a role in lupus nephritis (38). The generalized endothelial dysfunction that accompanies the microalbuminuria seen in early diabetic renal disease also suggests a contribution from a GEnC lesion (39). Endothelial damage is important in experimental immune glomerulonephritis (40) and in remnant kidney models, where it may initiate glomerulosclerosis (41). In some cases, endothelial regeneration accompanies glomerular repair (42) and may be essential for it (43). These observations suggest that endothelial growth factors may mitigate endothelial damage and promote recovery. Repair of glomerular capillaries in thy-1 nephritis is associated with increased VEGF expression (42), and endothelial damage caused by VEGF blockade is associated with upregulation of podocyte VEGF expression (13). Blocking VEGF slows recovery from experimental mesangioproliferative nephritis (44), whereas VEGF administration hastens recovery in a thy-1 habu snake venom model (43) and in experimental thrombotic microangiopathy (45). However, in models of diabetic nephropathy (where increased VEGF expression may be pathogenic), blockade of VEGF attenuates development of hyperfiltration, albuminuria, and the upregulation of endothelial nitric oxide synthase in GEnC (46, 47). These observations suggest that where there is significant GEnC loss, VEGF may be used to promote recovery, but where there is excess VEGF production, blockade may be appropriate. Ang1 may have particular application where

GEnC integrity is compromised, including where there is excess VEGF. In an animal model of diabetic retinopathy, ang1 had a profound effect in restoring integrity of the retinal EnC permeability barrier, normalizing VEGF levels, and counteracting many of the actions of VEGF (48). Thus, different combinations of mediators could be tailored for different glomerular diseases according to the particular pathology. Although further *in vitro* and *in vivo* work is required to define precisely the potential of such approaches in glomerular disease, VEGF is already in use in clinical trials in peripheral and cardiovascular disease (49).

In summary, these data confirm the potential of GEnC to respond to both ang1 and VEGF. The increase in GEnC monolayer integrity induced by ang1 is consistent with a role for ang1 *in vivo*, stabilizing the endothelium and resisting angiogenesis while allowing VEGF to induce the high permeability to water and small molecules that is characteristic of the glomerular endothelium. This study provides further evidence of the biologic plausibility of podocyte-produced factors crossing the glomerular basement membrane to have effects on the glomerular endothelium.

Acknowledgments

Some of the data presented have previously appeared in abstract form (J Am Soc Nephrol 13: 496A, 2002). S.C.S. was supported by a National Health Service South West Research and Development Executive grant. The work was performed at the Academic Renal Unit, University of Bristol. We thank Dr. D. Bates, Microvascular Research Laboratories, University of Bristol, UK, and Regeneron Pharmaceuticals Inc., Tarrytown, NY, for providing ang1*, which was used in preliminary experiments.

References

1. Visconti RP, Richardson CD, Sato TN: Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). *Proc Natl Acad Sci U S A* 99: 8219–8224, 2002
2. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. *Science* 284: 1994–1998, 1999
3. Satchell SC, Harper SJ, Mathieson PW: Angiopoietin-1 is normally expressed by periendothelial cells. *Thromb Haemost* 86: 1597–1598, 2001
4. Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS, Peters KG: Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. *Circ Res* 81: 567–574, 1997
5. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM, Yancopoulos GD: Angiopoietin-1 protects the adult vasculature against plasma leakage. *Nat Med* 6: 460–463, 2000
6. Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, McDonald DM: Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. *Science* 286: 2511–2514, 1999
7. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD: Angio-

- poietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. *Science* 277: 55–60, 1997
8. Petrova TV, Makinen T, Alitalo K: Signaling via vascular endothelial growth factor receptors. *Exp Cell Res* 253: 117–130, 1999
 9. Brown LF, Berse B, Tognazzi K, Manseau EJ, Van de Water L, Senger DR, Dvorak HF, Rosen S: Vascular permeability factor mRNA and protein expression in human kidney. *Kidney Int* 42: 1457–1461, 1992
 10. Satchell SC, Harper SJ, Tooke JE, Kerjaschki D, Saleem MA, Mathieson PW: Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular endothelial growth factor. *J Am Soc Nephrol* 13: 544–550, 2002
 11. Simon M, Grone HJ, Jöhren O, Kullmer J, Plate KH, Risau W, Fuchs E: Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. *Am J Physiol* 268: F240–F250, 1995
 12. Simon M, Rockl W, Hornig C, Grone EF, Theis H, Weich HA, Fuchs E, Yayon A, Grone HJ: Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: Localization and [¹²⁵I]VEGF binding sites. *J Am Soc Nephrol* 9: 1032–1044, 1998
 13. Kitamoto Y, Takeya M, Tokunaga H, Tomita K: Glomerular endothelial cells are maintained by vascular endothelial growth factor in the adult kidney. *Tohoku J Exp Med* 195: 43–54, 2001
 14. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R: Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. *J Biol Chem* 278: 12605–12608, 2003
 15. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. *J Clin Invest* 111: 707–716, 2003
 16. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. *J Clin Invest* 111: 649–658, 2003
 17. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. *N Engl J Med* 31: 427–434, 2003
 18. Ohlson M, Sorensson J, Haraldsson B: A gel-membrane model of glomerular charge and size selectivity in series. *Am J Physiol Renal Physiol* 280: F396–F405, 2001
 19. Deen WM, Lazzara MJ, Myers BD: Structural determinants of glomerular permeability. *Am J Physiol Renal Physiol* 281: F579–F596, 2001
 20. Rostgaard J, Qvortrup K: Electron microscopic demonstrations of filamentous molecular sieve plugs in capillary fenestrae. *Microvasc Res* 53: 1–13, 1997
 21. Sorensson J, Bjornson A, Ohlson M, Ballermann BJ, Haraldsson B: Synthesis of sulfated proteoglycans by bovine glomerular endothelial cells in culture. *Am J Physiol Renal Physiol* 284: F373–F380, 2003
 22. van Setten PA, van Hinsbergh VW, van der Velden TJ, van de Kar NC, Vermeer M, Mahan JD, Assmann KJ, van den Heuvel LP, Monnens LA: Effects of TNF alpha on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. *Kidney Int* 51: 1245–1256, 1997
 23. Ghitescu L, Robert M: Diversity in unity: The biochemical composition of the endothelial cell surface varies between the vascular beds. *Microsc Res Tech* 57: 381–389, 2002
 24. Page C, Rose M, Yacoub M, Pigott R: Antigenic heterogeneity of vascular endothelium. *Am J Pathol* 141: 673–683, 1992
 25. Kelly JJ, Moore TM, Babal P, Diwan AH, Stevens T, Thompson WJ: Pulmonary microvascular and macrovascular endothelial cells: Differential regulation of Ca²⁺ and permeability. *Am J Physiol* 274: L810–L819, 1998
 26. He P, Zeng M, Curry FE: Dominant role of cAMP in regulation of microvessel permeability. *Am J Physiol Heart Circ Physiol* 278: H1124–H1133, 2000
 27. van Nieuw Amerongen GP, Draijer R, Vermeer MA, van Hinsbergh VW: Transient and prolonged increase in endothelial permeability induced by histamine and thrombin: Role of protein kinases, calcium, and RhoA. *Circ Res* 83: 1115–1123, 1998
 28. Van Nieuw Amerongen GP, Van Hinsbergh VWM: Determination of endothelial barrier function in vitro. In: *Adhesion Protein Protocols*, Vol. 96, edited by Dejana E, Corada M, Totowa, Humana Press, 1999, pp 183–189
 29. Albelda SM, Sampson PM, Haselton FR, McNiff JM, Mueller SN, Williams SK, Fishman AP, Levine EM: Permeability characteristics of cultured endothelial cell monolayers. *J Appl Physiol* 64: 308–322, 1988
 30. Gillies MC, Su T, Naidoo D: Electrical resistance and macromolecular permeability of retinal capillary endothelial cells in vitro. *Curr Eye Res* 14: 435–442, 1995
 31. Cioffi DL, Moore TM, Schaack J, Creighton JR, Cooper DM, Stevens T: Dominant regulation of interendothelial cell gap formation by calcium-inhibited type 6 adenylyl cyclase. *J Cell Biol* 157: 1267–1278, 2002
 32. Moy AB, Shasby SS, Scott BD, Shasby DM: The effect of histamine and cyclic adenosine monophosphate on myosin light-chain phosphorylation in human umbilical vein endothelial cells. *J Clin Invest* 92: 1198–1206, 1993
 33. Gamble JR, Drew J, Trezise L, Underwood A, Parsons M, Kasminkas L, Rudge J, Yancopoulos G, Vadas MA: Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. *Circ Res* 87: 603–607, 2000
 34. Reusch P, Barleon B, Weindel K, Martiny-Baron G, Godde A, Siemeister G, Marme D: Identification of a soluble form of the angiopoietin receptor TIE-2 released from endothelial cells and present in human blood. *Angiogenesis* 4: 123–131, 2001
 35. Xu Y, Yu Q: Angiopoietin-1, unlike angiopoietin-2, is incorporated into the extracellular matrix via its linker peptide region. *J Biol Chem* 276: 34990–34998, 2001
 36. Chen J, Braet F, Brodsky S, Weinstein T, Romanov V, Noiri E, Goligorsky MS: VEGF-induced mobilization of caveolae and increase in permeability of endothelial cells. *Am J Physiol Cell Physiol* 282: C1053–C1063, 2002
 37. Bates DO, Hillman NJ, Williams B, Neal CR, Pocock TM: Regulation of microvascular permeability by vascular endothelial growth factors. *J Anat* 200: 581–597, 2002
 38. Perry GJ, Elston T, Khouri NA, Chan TM, Cameron JS, Framp-ton G: Antiendothelial cell antibodies in lupus: Correlations with renal injury and circulating markers of endothelial damage. *Q J Med* 86: 727–734, 1993
 39. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A: Albuminuria reflects widespread vascu-

- lar damage. The Steno hypothesis. *Diabetologia* 32: 219–226, 1989
40. Shimizu A, Kitamura H, Masuda Y, Ishizaki M, Sugisaki Y, Yamanaka N: Rare glomerular capillary regeneration and subsequent capillary regression with endothelial cell apoptosis in progressive glomerulonephritis. *Am J Pathol* 151: 1231–1239, 1997
 41. Lee LK, Meyer TW, Pollock AS, Lovett DH: Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. *J Clin Invest* 96: 953–964, 1995
 42. Iruela-Arispe L, Gordon K, Hugo C, Duijvestijn AM, Claffey KP, Reilly M, Couser WG, Alpers CE, Johnson RJ: Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. *Am J Pathol* 147: 1715–1727, 1995
 43. Masuda Y, Shimizu A, Mori T, Ishiwata T, Kitamura H, Ohashi R, Ishizaki M, Asano G, Sugisaki Y, Yamanaka N: Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. *Am J Pathol* 159: 599–608, 2001
 44. Ostendorf T, Kunter U, Eitner F, Loos A, Regele H, Kerjaschki D, Henninger DD, Janjic N, Floege J: VEGF(165) mediates glomerular endothelial repair. *J Clin Invest* 104: 913–923, 1999
 45. Kim YG, Suga SI, Kang DH, Jefferson JA, Mazzali M, Gordon KL, Matsui K, Breiteneder-Geleff S, Shankland SJ, Hughes J, Kerjaschki D, Schreiner GF, Johnson RJ: Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. *Kidney Int* 58: 2390–2399, 2000
 46. de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH: Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. *J Am Soc Nephrol* 12: 993–1000, 2001
 47. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R: Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. *Diabetes* 51: 3090–3094, 2002
 48. Jousen AM, Poulaki V, Tsujikawa A, Qin W, Qaum T, Xu Q, Moromizato Y, Bursell SE, Wiegand SJ, Rudge J, Ioffe E, Yancopoulos GD, Adamis AP: Suppression of diabetic retinopathy with angiopoietin-1. *Am J Pathol* 160: 1683–1693, 2002
 49. Ferrara N, Alitalo K: Clinical applications of angiogenic growth factors and their inhibitors. *Nat Med* 5: 1359–1364, 1999